Screen Reader Access
About us
Profile
Mission & Vision
Organisation Structure
Parent Organisation
Former Directors
Campus Tour
People
Director
Our Scientsts
Research Divisions
Cancer Biology
Endocrinology
Medicinal & Process Chemistry
Neuroscience & Ageing Biology
Pharmaceutics & Pharmacokinetics
Pharmacology
Toxicology & Experimental Medicine
Virus Research and Therapeutics
Sophisticated Analytical Instrument Facility & Research
Laboratory Animal Facility
Biochemistry & Structural Biology
Molecular Microbiology & Immunology
Administration
Technical & support Staff
Research
Malaria and other Parasitic Diseases
Antimicrobial Resistance
Virus Research and Therapeutics
Cancer Biology
Neuroscience and Ageing Biology
Cardiovascular System disorders
Bone Health
Reproductive Health
Pre-clinical Studies and Translation
Achievement
Drug
Technology
Diagnostics
Patents
Publications
Honours & Awards
Product Pipeline
Candidate Drug
Potential Lead
Formulation
Herbal
Patents
Business
Modes of Collaboration
Technologies Licensed
Glimpses
Contract Research
Consultancy
Services
Biological Screening
MoU list
Facilities & Services
Infrastructural Support Group
Academic Affair Unit
BD & IP Unit
Computer Centre
Knowledge Resource Centre (Library)
Laboratory Animals Facility
Human Resource Development
Scientific Directorate
Sophisticated Analytical Instrument Facility
Division of Institute Core Facility
Services for External Users
Pre Clinical Regulatory Studies
Clinical Trial Centers
National Laboratory Animal Center
GLP
Toxicology
Safety Pharmacology Studies
Bio Info & Computational Biology
X-Ray Crystallography
Library and Information Services
Biological screening
MAOs & MAEs for Embryology Training
Career
Prospective Scientist
Career Growth Opportunities
Prospective Scholar
PhD Program
Director's Message
Why CSIR-CDRI
Frequently Asked Questions
Campus Tour
Facilities
Prospective Project Staff
International Scholar
Introduction
Guidelines
Undertaking
Contact
Advance Training Programme
Training for Scholarship Awardees
Skill Development Program
Healthcare & Life Sciences
Postgraduate Students
Contact
Home
About us
Profile
Mission & Vision
Organisation Structure
Parent Organisation
Former Directors
Campus Tour
People
Director
Our Scientsts
Research Divisions
Cancer Biology
Endocrinology
Medicinal & Process Chemistry
Neuroscience & Ageing Biology
Pharmaceutics & Pharmacokinetics
Pharmacology
Toxicology & Experimental Medicine
Virus Research & Therapeutics
Sophisticated Analytical Instrument Facility & Research
Laboratory Animal Facility
Biochemistry & Structural Biology
Molecular Microbiology & Immunology
Administration
Technical & support Staff
Research
Malaria and other Parasitic Diseases
Antimicrobial Resistance
Virus Research & Therapeutics
Cancer Biology
Neuroscience and Ageing Biology
Cardiovascular System disorders
Bone Health
Reproductive Health
Pre-clinical Studies and Translation
Achievements
Drugs
Technologies
Diagnostics
Patents
Publications
Honours & Awards
Product Pipeline
Candidate Drug
Potential Lead
Formulation
Herbal
IPR
Business
Modes of Collaboration
Technologies Licensed
Glimpses
Contract Research
Consultancy
Services
Biological Screening
MoU list
Career
Prospective Scientist
Career Growth Opportunities
Prospective Scholar
PhD Program
Director's Message
Why CSIR-CDRI
Frequently Asked Questions
Campus Tour
Facilities
Prospective Project Staff
International Scholar
Introduction
Guidelines
Undertaking
Contact
Prospective Trainee
Advanced training
Skill Development Program
Healthcare & Life Sciences
Postgraduate Students
Facilities & Services
Services for External Users
Pre Clinical Regulatory Studies
Clinical Trial Centers
National Laboratory Animal Center
GLP
Infrastructural Support Group
Academic Affair Unit
BD & IP Unit
Computer Centre
Knowledge Resource Centre (Library)
Laboratory Animals
Human Resource Development
Scientific Directorate
Sophisticated Analytical Instrument Facility
Division of Institute Core Facility
Contact
Candidate Drug 97/78 (Anti-malarial)
Business
Candidate Drug 97/78 (Anti-malarial)
Candidate Drug 97/78 (Anti-malarial)
➤ Synthetic molecule (Artemesinine Derivative)
➤ Pre-Clinical Studies completed
➤ Pharmacologically safe, effective & Toxicologically safe
➤ Clinical Trial permission from DCGI to carry out Phase-I studies
➤ Phase-I Single dose clinical trial in normal healthy volunteers already completed along with human single dose pharmacokinetic studies..
➤ Safe in Phase-I single dose studies in normal healthy volunteers
Preamble
Malaria is one of the most widespread tropical parasitic diseases, caused by the protozoa of the genius plasmodium and transmitted by the female anopheles mosquito. According to the world malaria report 2011 of the World Health Organization (WHO), there were 216 million cases of malaria in the world in 2010. As much as 81% of these were in Africa and 13% is South-East Asia. There were an estimated 655,000 deaths in that year. Most of the deaths occurred in sub-Saharan Africa and the victims were mostly children under the age of five. Malaria remains the major public health problem in India. Northeastern region of India is one of the hot spots for malaria transmission. Focal outbreaks of malaria are of common occurrence especially in forest-fringed villages of Assam, bordering Arunachal Pradesh. Orissa alone contributes to more than 40% of P. falciparum deaths in India; south Orissa is a known as hyper-endemic area of the state.
Commonly used drugs to treat malaria are quinine (1), chloroquine (2) mefloquine (3), amodiaquine (4), primaquine (5), artemisinine (6), piperquine (7) dapsone (8) and sulfadiazine (9). But the rapidly increasing resistance of P. falciparum malaria parasites to drugs such as quinine, chloroquine, proguanil and pyrimethamine has made malaria chemotherapy ineffective. Most widely used antimalarial drugs, chloroquine (CQ) is a 4-aminoquinoline is the gold standard for the treatment of malaria that was previously characterized by its efficacy and low toxicity. But now malaria parasite developed resistance to Chloroquine with complex point mutations in the gene encoding PfCRT ultimately enhances efflux of Chloroquine from the food vacuole resulting low concentration of drug which makes the drug ineffective. Literature strongly suggests the involvement of compound specific resistance. To overcome the challenges in malaria chemotherapy in view of the fast growing resistance against existing drugs, there is an urgent need to develop new drugs. Structural modification of existing drugs offers promise for the development of new drugs as their mechanism of action, pharmacokinetic and toxicity profiles are already known.
Current Status
CDRI Comp 97/78 is a trioxane peroxide, a synthetic derivative of artemesinin. Pre-clinical regulatory studies have been completed. It is found safe in preclinical regulatory pharmacology and toxicity studies. DCGI permission to carry out phase-I clinical trial and pharmacokinetic studies has been obtained.
Phase-I single dose studies have been completed in PGIMER, Chandigarh and found safe and well-tolerated in normal healthy subjects. PK studies in normal healthy subjects in single dose shows rapid absorption and rapid conversion to its precursor 97/63; this confirmed preclinical data on the molecule. The higher t1/2 may help maintain the therapeutic efficacy and reduce the occurrence of recrudescence of malarial parasite during therapy and follow-up.
Candidate Drugs / Leads / Hits open for licensing
TITLE
INVENTOR(S)
APPLICATION NUMBER
FILING DATE
PATENT NUMBER
DATE OF GRANT
An improved process for the preparation of ether derivatives of dihydroartemisinin
Chandan Singh & Rani Kanchan
1258DEL1997
13-May-97
186127
25-Jan-02
Novel substituted 1,2,4- trioxanes useful as antimalarial agents
Chandan Singh & Sunil Kumar Puri
1579DEL1999
28-Dec-99
232539
18-Mar-09
BD-0058/2000
31-Mar-00
1003409/2000
ID-P-20000261
31-Mar-00
ID0011878
13-Oct-03
ML-PI-20001330
31-Mar-00
PK-819/2001 DIV
22-Aug-01
PK-0288/2000
31-Mar-00
137301
31-Jul-02
SG-200001862-2
31-Mar-00
SL-200001862.2
31-Mar-00
0084585
30-Sep-04
LK-12044
31-Mar-00
12044
27-Oct-00
TH-056618
31-Mar-00
US-09/539574
31-Mar-00
6316493
13-Nov-01
Vl-S20000281
31-Mar-00
VN-S20000281
31-Mar-00
4230
13-Apr-04
ZA-2000/1642
31-Mar-00
2000/1642
27-Dec-00